688041-31-8

Basic information

• Product Name: 1H-Imidazole-1-aceticacid,4-amino-,methylester(9CI)
• Synonyms: 1H-Imidazole-1-aceticacid,4-amino-,methylester(9CI)
• CAS NO: 688041-31-8
• Molecular Formula: C₆H₉N₃O₂
• Molecular Weight: 155.15
• Product Categories: GLYCINESCAFFOLD;AMINETERTIARY
• Mol File: 688041-31-8.mol

Chemical Properties

• Boiling Point: 379.5±22.0 °C(Predicted)
• Appearance: /
• Density: 1.34±0.1 g/cm3(Predicted)
• PKA: 6.85±0.61(Predicted)
• CAS DataBase Reference: 1H-Imidazole-1-aceticacid,4-amino-,methylester(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Imidazole-1-aceticacid,4-amino-,methylester(9CI)(688041-31-8)
• EPA Substance Registry System: 1H-Imidazole-1-aceticacid,4-amino-,methylester(9CI)(688041-31-8)

Safety Data

• Hazardous Substances Data: 688041-31-8(Hazardous Substances Data)

Usage

Structure

Ester derivative of 1H-Imidazole-1-acetic acid with an imidazole ring and an amino group

Usage

Building block in the synthesis of pharmaceuticals and agrochemicals

Applications

Medicinal chemistry, drug discovery, and interaction with biological systems, including protein targets

Safety

Handle with care and follow safety protocols to avoid health and environmental risks.

Upstream product

• 13230-21-2 (4-nitro-imidazol-1-yl)-acetic acid methyl ester 

Downstream Products

• 930100-40-6 C₁₉H₂₂F₂N₄O₄ 

Relevant articles and documents

Diamide amino-imidazoles: A novel series of γ-secretase inhibitors for the treatment of Alzheimers disease

The synthesis and structure-activity relationship (SAR) of a novel series of di-substituted imidazoles, derived from modification of DAPT, are described. Subsequent optimization led to identification of a highly potent series of inhibitors that contain a β-amine in the imidazole side-chain resulting in a robust in vivo reduction of plasma and brain Aβ in guinea pigs. The therapeutic index between Aβ reductions and changes in B-cell populations were studied for compound 10h.

IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS

The present invention relates to compounds of the Formula (I) wherein R1, R2, R3, R4, R5, R6, R7 and A are as defined. Compounds of the Formula (I) have activity inhibiting produ

Design and synthesis of heterocyclic hydroxamic acid derivatives as inhibitors of Helicobacter pylori urease

Helicobacter pylori produces ammonia to help counter the acidic environment in the human stomach. The production of ammonia, essential for the microorganism's survival and virulence, is the product of enzymatic conversion of urea by the H. pylori's urease. Inhibition of urease activity by dipeptide hydroxamic acids has previously been demonstrated using a variety of fluorides, thiols and hydroxamic acids. Studies employing computer-aided drug design techniques have been utilized to suggest a novel series of heterocyclic hydroxamic acid derivatives as potential as urease inhibitors. The heterocyclic compounds 7a,b, 10b, 12b, 16b, and 19b have been designed, synthesized, and preliminarily tested as dipeptide mimics which offer a structure that is more biologically stable than that of the reported dipeptide inhibitors.